wendesdayTomahawk, WI 3/20/2013 (Expedated) – Welcome to Wednesday, its all downhill from here. Here is a look at the morning movers.

The first stock we take a look at is Model N (MODN.N) which is up over 34% on the day of their debut. This has brought the company nearly half-a-billion dollars.

Francis Gaskins, a partner at IPODesktop.com, an IPO research company commented; “They’re very unique. They’ve carved out pretty much an impenetrable market position in the life sciences area and they’re taking that success pattern into other vertical markets such as technology.”  The company is also moving more into cloud, which is always of great interest to investors, because that’s based more on subscription revenue with additional recurring earnings.”

Model N is a company that provides revenue management software to life science and technology companies to help manage pricing, deals, contracts and rebates.

Valeant Pharmaceuticals International (VRX)  just announced that it’s buying skin-cream maker Obagi Medical Products (OMPI) for $344 million driving the stocks value up over 27% in morning trading.

Valeant CEO J. Michael Pearson said; The acquisition of Obagi will be a valuable supplement to Valeant’s current dermatology portfolio and will further build upon our growing aesthetics franchise.” Obagi is best known for Nu-Derm, a topical prescription treatment for wrinkles and skin blotches. The company also sells products that complement injections of dermal fillers and botulinum toxins.

Last but not least we find Gevo Inc. (GEVO) trading up in value over 10% this morning on a federal court ruling.  The U.S. biofuel producer, partly prevailed in its bid for a federal court ruling saying that it doesn’t infringe on a Butamax Advanced Biofuels LLC patent for a method to commercially produce isobutanol.

Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. They are my opinions only. Trading stocks is risky — always be sure to know and understand your risk tolerance. You can incur substantial financial losses in any trade or investment. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser.

 

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.